SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/55936"
 

Search: onr:"swepub:oai:gup.ub.gu.se/55936" > The effects of losa...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Kjeldsen, S. E. (author)

The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study

  • Article/chapterEnglish2005

Publisher, publication year, extent ...

  • 2005

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/55936
  • https://gup.ub.gu.se/publication/55936URI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study reported that a losartan-based antihypertensive regimen reduced cardiovascular morbidity and mortality (composite of cardiovascular death, stroke, and myocardial infarction) more than therapy based on atenolol in patients with left ventricular hypertrophy and isolated systolic hypertension (ISH). Patients aged 55-80 years with blood pressures 160-200/<90 mm Hg were followed for a mean of 4.7 years. Blood pressure was similarly reduced in the losartan (n=660) and atenolol (n=666) ISH groups. There were 88 (6.6%) patients who experienced a stroke, 18 of which were fatal. Of patients experiencing strokes, 72.7% had an ischemic stroke. ISH patients in LIFE compared to the non-ISH group had a higher incidence of any stroke and embolic stroke, and similar incidences of fatal, atherosclerotic, and hemorrhagic/other strokes. The incidence of any stroke (40% risk reduction [RR], p=0.02), fatal stroke (70% RR, p=0.035), and atherothrombotic stroke (45% RR, p=0.022) was significantly lower in losartan-treated compared to the atenolol-treated patients. The 36% RR for embolic strokes in the losartan group was not statistically significantly (p=0.33) different from the atenolol group. These data suggest that losartan-based treatment is more effective than an atenolol-based treatment for patients with ISH and a high risk for stroke.

Subject headings and genre

  • Aged
  • Aged
  • 80 and over
  • Antihypertensive Agents/*therapeutic use
  • Atenolol/*therapeutic use
  • Blood Pressure/*drug effects
  • Cerebrovascular Accident/epidemiology/*prevention & control
  • Confounding Factors (Epidemiology)
  • Double-Blind Method
  • Female
  • Humans
  • Hypertension/*drug therapy
  • Hypertrophy
  • Left Ventricular/*drug therapy
  • Losartan/*therapeutic use
  • Male
  • Middle Aged
  • Multicenter Studies
  • Systole/drug effects
  • Treatment Outcome

Added entries (persons, corporate bodies, meetings, titles ...)

  • Lyle, P. A. (author)
  • Kizer, J. R. (author)
  • Dahlöf, Björn,1953Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Cardiovascular Institute(Swepub:gu)xdahbj (author)
  • Devereux, R. B. (author)
  • Julius, S. (author)
  • Beevers, G. (author)
  • de Faire, U. (author)
  • Fyhrquist, F. (author)
  • Ibsen, H. (author)
  • Kristianson, K. (author)
  • Lederballe-Pedersen, O. (author)
  • Lindholm, L. H. (author)
  • Nieminen, M. S. (author)
  • Omvik, P. (author)
  • Oparil, S. (author)
  • Snapinn, S. M. (author)
  • Harris, K. E. (author)
  • Wedel, H. (author)
  • Göteborgs universitetHjärt-kärlinstitutionen (creator_code:org_t)

Related titles

  • In:J Clin Hypertens (Greenwich)7:3, s. 152-81524-6175

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view